R&D Trends

BMS, Vanderbilt University to develop novel treatments for Parkinson's

Tuesday, September 25, 2012 11:28 AM

Vanderbilt University of Nashville, Tenn., and global biopharmaceutical company Bristol-Myers Squibb (BMS) have signed a collaboration agreement for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive allosteric modulators or PAMs, for the treatment of Parkinson's disease.

More... »

Sanofi, TB Alliance collaborate to accelerate new treatments for TB

Monday, September 24, 2012 08:00 AM

Global healthcare company Sanofi and the not-for-profit organization Global Alliance for TB Drug Development (TB Alliance) have formed a new research collaboration agreement to accelerate the discovery and development of novel compounds against tuberculosis (TB).

More... »

Constellation, LLS to develop novel BET inhibitor for hematologic malignancies

Friday, September 21, 2012 01:12 PM

Constellation Pharmaceuticals, a Cambridge, Mass.-based biopharmaceutical company in the field of epigenetics, has entered into a strategic partnership with the Leukemia & Lymphoma Society (LLS) to advance the development of a novel BET inhibitor for the treatment of patients with hematologic malignancies.

More... »

Emory to receive $6 million for AIDS vaccine research

Friday, September 21, 2012 11:04 AM

A team of researchers at Emory University has received a three-year grant of $6 million from the Bill & Melinda Gates Foundation as part of the Collaboration for AIDS Vaccine Discovery (CAVD), an international network of scientists and experts dedicated to developing an effective vaccine for HIV/AIDS.

More... »

Wellington Partners announces first closing of new life science fund

Thursday, September 20, 2012 07:31 AM

Wellington Partners, a pan-European venture capital firm, announced the successful first closing of its new Wellington Partners IV Life Science Fund, which has attracted commitments from investors of $91 million.

More... »

10 pharmas form nonprofit TransCelerate to accelerate R&D of new medicines

Wednesday, September 19, 2012 02:46 PM

Ten biopharmaceutical companies have formed a non-profit organization, TransCelerate BioPharma, to accelerate the development of new medicines. Participants include Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech and Sanofi.

More... »

Mutabilis receives $5.2M from E.U. for HIVINNOV project

Wednesday, September 19, 2012 11:06 AM

Mutabilis, a spin-off from INSERM that focuses on therapeutics for treating serious, hospital-acquired infections, has received $5.2 million of European funding for the HIVINNOV project, aimed at developing new antiretrovirals against HIV.

More... »

J&J s to establish innovation centers

Wednesday, September 19, 2012 10:14 AM

Johnson & Johnson is planning to establish four regional innovation centers in major life sciences communities in the world as part of a novel approach to accelerate early innovation and enhance opportunities for collaboration and investment across its global healthcare businesses.

More... »

PPD, GA2LEN form strategic alliance in allergic diseases

Monday, September 17, 2012 10:38 AM

Pharmaceutical Product Development (PPD), a global CRO, and the Global Allergy and Asthma European Network (GA²LEN), a multidisciplinary research network, have formed a strategic alliance in which GA²LEN will provide PPD access to the network's allergy and asthma experts and to more than 100 allergy and asthma sites in Europe.

More... »

Oncodesign, Sanofi ink research collaboration and license agreement

Friday, September 14, 2012 11:57 AM

Oncodesign, a French drug discovery company and oncology pharmacology service provider, has entered into a strategic research collaboration with global healthcare company Sanofi to apply Oncodesign's Nanocyclix technology to Sanofi kinase target programs.

More... »